# Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial

Study · id `cardio:ct-nct04696120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04696120](<https://clinicaltrials.gov/study/NCT04696120>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04696120

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04696120. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-02 (anticipated); primary completion 2022-08-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04696120, source copy `cardio:ctgov-nct04696120-2021-01-20`, retrieved 2026-10-26)
- Planned start: 2021-03-02 (anticipated) (ClinicalTrials.gov record NCT04696120, source copy `cardio:ctgov-nct04696120-2021-01-20`, retrieved 2026-10-26)
- Primary completion: 2022-08-30 (anticipated) (ClinicalTrials.gov record NCT04696120, source copy `cardio:ctgov-nct04696120-2021-01-20`, retrieved 2026-10-26)
- Completion: 2023-02-28 (anticipated) (ClinicalTrials.gov record NCT04696120, source copy `cardio:ctgov-nct04696120-2021-01-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04696120, source copy `cardio:ctgov-nct04696120-2021-01-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04696120-2021-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial
- Condition: Heart Failure
- Condition: Sinus Rhythm
- Condition: Cerebrovascular Disease
- Intervention (Drug): Apixaban
- Intervention (Drug): Placebo
- Lead sponsor: Korea University Guro Hospital
- Lead sponsor class: OTHER
- Collaborator: Dt&Sanomedics
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Korea University Guro Hospital (`cardio:org-korea-university-guro-hospital`)

## Provenance

Content hash: 3b69a9202a571461872d992338c8708350bb1d8bbe848cb391f49effdf6e1b56
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
